Covid-19 Impact on Global Drugs for Oncology Market Size, Status and Forecast 2020-2026
Drugs for Oncology market is segmented by Type, and by Application. Players, stakeholders, and other participants in the global Drugs for Oncology market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on revenue and forecast by Type and by Application in terms of revenue and forecast for the period 2015-2026.
Since the COVID-19 virus outbreak in December 2019, the disease has spread to almost 200 countries around the globe with the World Health Organization declaring it a public health emergency. The global impacts of the coronavirus disease 2019 (COVID-19) are already starting to be felt, and will significantly affect the Drugs for Oncology market in 2020. The outbreak of COVID-19 has brought effects on many aspects, like flight cancellations; travel bans and quarantines; restaurants closed; all indoor events restricted; over forty countries state of emergency declared; massive slowing of the supply chain; stock market volatility; falling business confidence, growing panic among the population, and uncertainty about future.
This report also analyzes the impact of Coronavirus COVID-19 on the Drugs for Oncology industry.
The key players covered in this study
History Year: 2015-2019
Base Year: 2019
Estimated Year: 2020
Forecast Year 2020 to 2026
For the data information by region, company, type and application, 2019 is considered as the base year. Whenever data information was unavailable for the base year, the prior year has been considered.
Since the COVID-19 virus outbreak in December 2019, the disease has spread to almost 200 countries around the globe with the World Health Organization declaring it a public health emergency. The global impacts of the coronavirus disease 2019 (COVID-19) are already starting to be felt, and will significantly affect the Drugs for Oncology market in 2020. The outbreak of COVID-19 has brought effects on many aspects, like flight cancellations; travel bans and quarantines; restaurants closed; all indoor events restricted; over forty countries state of emergency declared; massive slowing of the supply chain; stock market volatility; falling business confidence, growing panic among the population, and uncertainty about future.
This report also analyzes the impact of Coronavirus COVID-19 on the Drugs for Oncology industry.
The key players covered in this study
- Roche
- Celgene
- Novartis
- Bristol-Myers Squibb
- Johnson & Johnson
- Merck & Co.
- AstraZeneca
- Pfizer
- Amgen
- Eli Lilly
- AbbVie
- Takeda
- Astellas
- Ipsen
- Sanofi
- Bayer
- Biogen Idec
- Teva
- Otsuka
- Eisai
- Merck KGaA
- Gilead Sciences
- Chemotherapy
- Targeted Therapy
- Immunotherapy (Biologic Therapy)
- Hormonal Therapy
- Others
- Blood Cancer
- Breast Cancer
- Gastrointestinal Cancer
- Prostate Cancer
- Respiratory/Lung Cancer
- Others
- North America
- Europe
- China
- Japan
- Southeast Asia
- India
- Central & South America
- To analyze global Drugs for Oncology status, future forecast, growth opportunity, key market and key players.
- To present the Drugs for Oncology development in North America, Europe, China, Japan, Southeast Asia, India and Central & South America.
- To define, describe and forecast the market by type, market and key regions.
History Year: 2015-2019
Base Year: 2019
Estimated Year: 2020
Forecast Year 2020 to 2026
For the data information by region, company, type and application, 2019 is considered as the base year. Whenever data information was unavailable for the base year, the prior year has been considered.
1 REPORT OVERVIEW
1.1 Study Scope
1.2 Key Market Segments
1.3 Players Covered: Ranking by Drugs for Oncology Revenue
1.4 Covid-19 Implications on Market by Type
1.4.1 Global Drugs for Oncology Market Size Growth Rate by Type: 2020 VS 2026
1.4.2 Chemotherapy
1.4.3 Targeted Therapy
1.4.4 Immunotherapy (Biologic Therapy)
1.4.5 Hormonal Therapy
1.4.6 Others
1.5 Market by Application
1.5.1 Global Drugs for Oncology Market Share by Application: 2020 VS 2026
1.5.2 Blood Cancer
1.5.3 Breast Cancer
1.5.4 Gastrointestinal Cancer
1.5.5 Prostate Cancer
1.5.6 Respiratory/Lung Cancer
1.5.7 Others
1.6 Coronavirus Disease 2019 (Covid-19): Drugs for Oncology Industry Impact
1.6.1 Covid-19 Impact: Global GDP Growth, 2019, 2020 and 2021 Projections
1.6.2 Covid-19 Impact: Commodity Prices Indices
1.6.3 Covid-19 Impact: Global Major Government Policy
1.7 Study Objectives
1.8 Years Considered
2 GLOBAL GROWTH TRENDS
2.1 Covid-19 Implications on Global Drugs for Oncology Market Perspective (2015-2026)
2.2 Covid-19 Implications on Global Drugs for Oncology Growth Trends by Regions
2.2.1 Drugs for Oncology Market Size by Regions: 2015 VS 2020 VS 2026
2.2.2 Drugs for Oncology Historic Market Share by Regions (2015-2020)
2.2.3 Drugs for Oncology Forecasted Market Size by Regions (2021-2026)
2.3 Industry Trends and Growth Strategy
2.3.1 Market Top Trends
2.3.2 Market Drivers
2.3.3 Market Challenges
2.3.4 Porter’s Five Forces Analysis
2.3.5 Drugs for Oncology Market Growth Strategy
2.3.6 Primary Interviews with Key Drugs for Oncology Players (Opinion Leaders)
3 COVID-19 IMPLICATIONS ON COMPETITION LANDSCAPE BY KEY PLAYERS
3.1 Global Top Drugs for Oncology Players by Market Size
3.1.1 Global Top Drugs for Oncology Players by Revenue (2015-2020)
3.1.2 Global Drugs for Oncology Revenue Market Share by Players (2015-2020)
3.1.3 Global Drugs for Oncology Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
3.2 Global Drugs for Oncology Market Concentration Ratio
3.2.1 Global Drugs for Oncology Market Concentration Ratio (CR5 and HHI)
3.2.2 Global Top 10 and Top 5 Companies by Drugs for Oncology Revenue in 2019
3.3 Drugs for Oncology Key Players Head office and Area Served
3.4 Key Players Drugs for Oncology Product Solution and Service
3.5 Date of Enter into Drugs for Oncology Market
3.6 Mergers & Acquisitions, Expansion Plans
4 COVID-19 IMPLICATIONS ON MARKET SIZE BY TYPE (2015-2026)
4.1 Global Drugs for Oncology Historic Market Size by Type (2015-2020)
4.2 Global Drugs for Oncology Forecasted Market Size by Type (2021-2026)
5 COVID-19 IMPLICATIONS ON MARKET SIZE BY APPLICATION (2015-2026)
5.1 Global Drugs for Oncology Market Size by Application (2015-2020)
5.2 Global Drugs for Oncology Forecasted Market Size by Application (2021-2026)
6 NORTH AMERICA IMPACT OF COVID-19
6.1 North America Drugs for Oncology Market Size (2015-2020)
6.2 Drugs for Oncology Key Players in North America (2019-2020)
6.3 North America Drugs for Oncology Market Size by Type (2015-2020)
6.4 North America Drugs for Oncology Market Size by Application (2015-2020)
7 EUROPE IMPACT OF COVID-19
7.1 Europe Drugs for Oncology Market Size (2015-2020)
7.2 Drugs for Oncology Key Players in Europe (2019-2020)
7.3 Europe Drugs for Oncology Market Size by Type (2015-2020)
7.4 Europe Drugs for Oncology Market Size by Application (2015-2020)
8 CHINA IMPACT OF COVID-19
8.1 China Drugs for Oncology Market Size (2015-2020)
8.2 Drugs for Oncology Key Players in China (2019-2020)
8.3 China Drugs for Oncology Market Size by Type (2015-2020)
8.4 China Drugs for Oncology Market Size by Application (2015-2020)
9 JAPAN IMPACT OF COVID-19
9.1 Japan Drugs for Oncology Market Size (2015-2020)
9.2 Drugs for Oncology Key Players in Japan (2019-2020)
9.3 Japan Drugs for Oncology Market Size by Type (2015-2020)
9.4 Japan Drugs for Oncology Market Size by Application (2015-2020)
10 SOUTHEAST ASIA IMPACT OF COVID-19
10.1 Southeast Asia Drugs for Oncology Market Size (2015-2020)
10.2 Drugs for Oncology Key Players in Southeast Asia (2019-2020)
10.3 Southeast Asia Drugs for Oncology Market Size by Type (2015-2020)
10.4 Southeast Asia Drugs for Oncology Market Size by Application (2015-2020)
11 INDIA IMPACT OF COVID-19
11.1 India Drugs for Oncology Market Size (2015-2020)
11.2 Drugs for Oncology Key Players in India (2019-2020)
11.3 India Drugs for Oncology Market Size by Type (2015-2020)
11.4 India Drugs for Oncology Market Size by Application (2015-2020)
12 CENTRAL & SOUTH AMERICA IMPACT OF COVID-19
12.1 Central & South America Drugs for Oncology Market Size (2015-2020)
12.2 Drugs for Oncology Key Players in Central & South America (2019-2020)
12.3 Central & South America Drugs for Oncology Market Size by Type (2015-2020)
12.4 Central & South America Drugs for Oncology Market Size by Application (2015-2020)
13KEY PLAYERS PROFILES
13.1 Roche
13.1.1 Roche Company Details
13.1.2 Roche Business Overview and Its Total Revenue
13.1.3 Roche Drugs for Oncology Introduction
13.1.4 Roche Revenue in Drugs for Oncology Business (2015-2020))
13.1.5 Roche Recent Development and Reaction to COVID-19
13.2 Celgene
13.2.1 Celgene Company Details
13.2.2 Celgene Business Overview and Its Total Revenue
13.2.3 Celgene Drugs for Oncology Introduction
13.2.4 Celgene Revenue in Drugs for Oncology Business (2015-2020)
13.2.5 Celgene Recent Development and Reaction to COVID-19
13.3 Novartis
13.3.1 Novartis Company Details
13.3.2 Novartis Business Overview and Its Total Revenue
13.3.3 Novartis Drugs for Oncology Introduction
13.3.4 Novartis Revenue in Drugs for Oncology Business (2015-2020)
13.3.5 Novartis Recent Development and Reaction to COVID-19
13.4 Bristol-Myers Squibb
13.4.1 Bristol-Myers Squibb Company Details
13.4.2 Bristol-Myers Squibb Business Overview and Its Total Revenue
13.4.3 Bristol-Myers Squibb Drugs for Oncology Introduction
13.4.4 Bristol-Myers Squibb Revenue in Drugs for Oncology Business (2015-2020)
13.4.5 Bristol-Myers Squibb Recent Development and Reaction to COVID-19
13.5 Johnson & Johnson
13.5.1 Johnson & Johnson Company Details
13.5.2 Johnson & Johnson Business Overview and Its Total Revenue
13.5.3 Johnson & Johnson Drugs for Oncology Introduction
13.5.4 Johnson & Johnson Revenue in Drugs for Oncology Business (2015-2020)
13.5.5 Johnson & Johnson Recent Development and Reaction to COVID-19
13.6 Merck & Co.
13.6.1 Merck & Co. Company Details
13.6.2 Merck & Co. Business Overview and Its Total Revenue
13.6.3 Merck & Co. Drugs for Oncology Introduction
13.6.4 Merck & Co. Revenue in Drugs for Oncology Business (2015-2020)
13.6.5 Merck & Co. Recent Development and Reaction to COVID-19
13.7 AstraZeneca
13.7.1 AstraZeneca Company Details
13.7.2 AstraZeneca Business Overview and Its Total Revenue
13.7.3 AstraZeneca Drugs for Oncology Introduction
13.7.4 AstraZeneca Revenue in Drugs for Oncology Business (2015-2020)
13.7.5 AstraZeneca Recent Development and Reaction to COVID-19
13.8 Pfizer
13.8.1 Pfizer Company Details
13.8.2 Pfizer Business Overview and Its Total Revenue
13.8.3 Pfizer Drugs for Oncology Introduction
13.8.4 Pfizer Revenue in Drugs for Oncology Business (2015-2020)
13.8.5 Pfizer Recent Development and Reaction to COVID-19
13.9 Amgen
13.9.1 Amgen Company Details
13.9.2 Amgen Business Overview and Its Total Revenue
13.9.3 Amgen Drugs for Oncology Introduction
13.9.4 Amgen Revenue in Drugs for Oncology Business (2015-2020)
13.9.5 Amgen Recent Development and Reaction to COVID-19
13.10 Eli Lilly
13.10.1 Eli Lilly Company Details
13.10.2 Eli Lilly Business Overview and Its Total Revenue
13.10.3 Eli Lilly Drugs for Oncology Introduction
13.10.4 Eli Lilly Revenue in Drugs for Oncology Business (2015-2020)
13.10.5 Eli Lilly Recent Development and Reaction to COVID-19
13.11 AbbVie
10.11.1 AbbVie Company Details
10.11.2 AbbVie Business Overview and Its Total Revenue
10.11.3 AbbVie Drugs for Oncology Introduction
10.11.4 AbbVie Revenue in Drugs for Oncology Business (2015-2020)
10.11.5 AbbVie Recent Development and Reaction to COVID-19
13.12 Takeda
10.12.1 Takeda Company Details
10.12.2 Takeda Business Overview and Its Total Revenue
10.12.3 Takeda Drugs for Oncology Introduction
10.12.4 Takeda Revenue in Drugs for Oncology Business (2015-2020)
10.12.5 Takeda Recent Development and Reaction to COVID-19
13.13 Astellas
10.13.1 Astellas Company Details
10.13.2 Astellas Business Overview and Its Total Revenue
10.13.3 Astellas Drugs for Oncology Introduction
10.13.4 Astellas Revenue in Drugs for Oncology Business (2015-2020)
10.13.5 Astellas Recent Development and Reaction to COVID-19
13.14 Ipsen
10.14.1 Ipsen Company Details
10.14.2 Ipsen Business Overview and Its Total Revenue
10.14.3 Ipsen Drugs for Oncology Introduction
10.14.4 Ipsen Revenue in Drugs for Oncology Business (2015-2020)
10.14.5 Ipsen Recent Development and Reaction to COVID-19
13.15 Sanofi
10.15.1 Sanofi Company Details
10.15.2 Sanofi Business Overview and Its Total Revenue
10.15.3 Sanofi Drugs for Oncology Introduction
10.15.4 Sanofi Revenue in Drugs for Oncology Business (2015-2020)
10.15.5 Sanofi Recent Development and Reaction to COVID-19
13.16 Bayer
10.16.1 Bayer Company Details
10.16.2 Bayer Business Overview and Its Total Revenue
10.16.3 Bayer Drugs for Oncology Introduction
10.16.4 Bayer Revenue in Drugs for Oncology Business (2015-2020)
10.16.5 Bayer Recent Development and Reaction to COVID-19
13.17 Biogen Idec
10.17.1 Biogen Idec Company Details
10.17.2 Biogen Idec Business Overview and Its Total Revenue
10.17.3 Biogen Idec Drugs for Oncology Introduction
10.17.4 Biogen Idec Revenue in Drugs for Oncology Business (2015-2020)
10.17.5 Biogen Idec Recent Development and Reaction to COVID-19
13.18 Teva
10.18.1 Teva Company Details
10.18.2 Teva Business Overview and Its Total Revenue
10.18.3 Teva Drugs for Oncology Introduction
10.18.4 Teva Revenue in Drugs for Oncology Business (2015-2020)
10.18.5 Teva Recent Development and Reaction to COVID-19
13.19 Otsuka
10.19.1 Otsuka Company Details
10.19.2 Otsuka Business Overview and Its Total Revenue
10.19.3 Otsuka Drugs for Oncology Introduction
10.19.4 Otsuka Revenue in Drugs for Oncology Business (2015-2020)
10.19.5 Otsuka Recent Development and Reaction to COVID-19
13.20 Eisai
10.20.1 Eisai Company Details
10.20.2 Eisai Business Overview and Its Total Revenue
10.20.3 Eisai Drugs for Oncology Introduction
10.20.4 Eisai Revenue in Drugs for Oncology Business (2015-2020)
10.20.5 Eisai Recent Development and Reaction to COVID-19
13.21 Merck KGaA
10.21.1 Merck KGaA Company Details
10.21.2 Merck KGaA Business Overview and Its Total Revenue
10.21.3 Merck KGaA Drugs for Oncology Introduction
10.21.4 Merck KGaA Revenue in Drugs for Oncology Business (2015-2020)
10.21.5 Merck KGaA Recent Development and Reaction to COVID-19
13.22 Gilead Sciences
10.22.1 Gilead Sciences Company Details
10.22.2 Gilead Sciences Business Overview and Its Total Revenue
10.22.3 Gilead Sciences Drugs for Oncology Introduction
10.22.4 Gilead Sciences Revenue in Drugs for Oncology Business (2015-2020)
10.22.5 Gilead Sciences Recent Development and Reaction to COVID-19
14ANALYST'S VIEWPOINTS/CONCLUSIONS
15APPENDIX
15.1 Research Methodology
15.1.1 Methodology/Research Approach
15.1.2 Data Source
15.2 Disclaimer
15.3 Author Details
1.1 Study Scope
1.2 Key Market Segments
1.3 Players Covered: Ranking by Drugs for Oncology Revenue
1.4 Covid-19 Implications on Market by Type
1.4.1 Global Drugs for Oncology Market Size Growth Rate by Type: 2020 VS 2026
1.4.2 Chemotherapy
1.4.3 Targeted Therapy
1.4.4 Immunotherapy (Biologic Therapy)
1.4.5 Hormonal Therapy
1.4.6 Others
1.5 Market by Application
1.5.1 Global Drugs for Oncology Market Share by Application: 2020 VS 2026
1.5.2 Blood Cancer
1.5.3 Breast Cancer
1.5.4 Gastrointestinal Cancer
1.5.5 Prostate Cancer
1.5.6 Respiratory/Lung Cancer
1.5.7 Others
1.6 Coronavirus Disease 2019 (Covid-19): Drugs for Oncology Industry Impact
1.6.1 Covid-19 Impact: Global GDP Growth, 2019, 2020 and 2021 Projections
1.6.2 Covid-19 Impact: Commodity Prices Indices
1.6.3 Covid-19 Impact: Global Major Government Policy
1.7 Study Objectives
1.8 Years Considered
2 GLOBAL GROWTH TRENDS
2.1 Covid-19 Implications on Global Drugs for Oncology Market Perspective (2015-2026)
2.2 Covid-19 Implications on Global Drugs for Oncology Growth Trends by Regions
2.2.1 Drugs for Oncology Market Size by Regions: 2015 VS 2020 VS 2026
2.2.2 Drugs for Oncology Historic Market Share by Regions (2015-2020)
2.2.3 Drugs for Oncology Forecasted Market Size by Regions (2021-2026)
2.3 Industry Trends and Growth Strategy
2.3.1 Market Top Trends
2.3.2 Market Drivers
2.3.3 Market Challenges
2.3.4 Porter’s Five Forces Analysis
2.3.5 Drugs for Oncology Market Growth Strategy
2.3.6 Primary Interviews with Key Drugs for Oncology Players (Opinion Leaders)
3 COVID-19 IMPLICATIONS ON COMPETITION LANDSCAPE BY KEY PLAYERS
3.1 Global Top Drugs for Oncology Players by Market Size
3.1.1 Global Top Drugs for Oncology Players by Revenue (2015-2020)
3.1.2 Global Drugs for Oncology Revenue Market Share by Players (2015-2020)
3.1.3 Global Drugs for Oncology Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
3.2 Global Drugs for Oncology Market Concentration Ratio
3.2.1 Global Drugs for Oncology Market Concentration Ratio (CR5 and HHI)
3.2.2 Global Top 10 and Top 5 Companies by Drugs for Oncology Revenue in 2019
3.3 Drugs for Oncology Key Players Head office and Area Served
3.4 Key Players Drugs for Oncology Product Solution and Service
3.5 Date of Enter into Drugs for Oncology Market
3.6 Mergers & Acquisitions, Expansion Plans
4 COVID-19 IMPLICATIONS ON MARKET SIZE BY TYPE (2015-2026)
4.1 Global Drugs for Oncology Historic Market Size by Type (2015-2020)
4.2 Global Drugs for Oncology Forecasted Market Size by Type (2021-2026)
5 COVID-19 IMPLICATIONS ON MARKET SIZE BY APPLICATION (2015-2026)
5.1 Global Drugs for Oncology Market Size by Application (2015-2020)
5.2 Global Drugs for Oncology Forecasted Market Size by Application (2021-2026)
6 NORTH AMERICA IMPACT OF COVID-19
6.1 North America Drugs for Oncology Market Size (2015-2020)
6.2 Drugs for Oncology Key Players in North America (2019-2020)
6.3 North America Drugs for Oncology Market Size by Type (2015-2020)
6.4 North America Drugs for Oncology Market Size by Application (2015-2020)
7 EUROPE IMPACT OF COVID-19
7.1 Europe Drugs for Oncology Market Size (2015-2020)
7.2 Drugs for Oncology Key Players in Europe (2019-2020)
7.3 Europe Drugs for Oncology Market Size by Type (2015-2020)
7.4 Europe Drugs for Oncology Market Size by Application (2015-2020)
8 CHINA IMPACT OF COVID-19
8.1 China Drugs for Oncology Market Size (2015-2020)
8.2 Drugs for Oncology Key Players in China (2019-2020)
8.3 China Drugs for Oncology Market Size by Type (2015-2020)
8.4 China Drugs for Oncology Market Size by Application (2015-2020)
9 JAPAN IMPACT OF COVID-19
9.1 Japan Drugs for Oncology Market Size (2015-2020)
9.2 Drugs for Oncology Key Players in Japan (2019-2020)
9.3 Japan Drugs for Oncology Market Size by Type (2015-2020)
9.4 Japan Drugs for Oncology Market Size by Application (2015-2020)
10 SOUTHEAST ASIA IMPACT OF COVID-19
10.1 Southeast Asia Drugs for Oncology Market Size (2015-2020)
10.2 Drugs for Oncology Key Players in Southeast Asia (2019-2020)
10.3 Southeast Asia Drugs for Oncology Market Size by Type (2015-2020)
10.4 Southeast Asia Drugs for Oncology Market Size by Application (2015-2020)
11 INDIA IMPACT OF COVID-19
11.1 India Drugs for Oncology Market Size (2015-2020)
11.2 Drugs for Oncology Key Players in India (2019-2020)
11.3 India Drugs for Oncology Market Size by Type (2015-2020)
11.4 India Drugs for Oncology Market Size by Application (2015-2020)
12 CENTRAL & SOUTH AMERICA IMPACT OF COVID-19
12.1 Central & South America Drugs for Oncology Market Size (2015-2020)
12.2 Drugs for Oncology Key Players in Central & South America (2019-2020)
12.3 Central & South America Drugs for Oncology Market Size by Type (2015-2020)
12.4 Central & South America Drugs for Oncology Market Size by Application (2015-2020)
13KEY PLAYERS PROFILES
13.1 Roche
13.1.1 Roche Company Details
13.1.2 Roche Business Overview and Its Total Revenue
13.1.3 Roche Drugs for Oncology Introduction
13.1.4 Roche Revenue in Drugs for Oncology Business (2015-2020))
13.1.5 Roche Recent Development and Reaction to COVID-19
13.2 Celgene
13.2.1 Celgene Company Details
13.2.2 Celgene Business Overview and Its Total Revenue
13.2.3 Celgene Drugs for Oncology Introduction
13.2.4 Celgene Revenue in Drugs for Oncology Business (2015-2020)
13.2.5 Celgene Recent Development and Reaction to COVID-19
13.3 Novartis
13.3.1 Novartis Company Details
13.3.2 Novartis Business Overview and Its Total Revenue
13.3.3 Novartis Drugs for Oncology Introduction
13.3.4 Novartis Revenue in Drugs for Oncology Business (2015-2020)
13.3.5 Novartis Recent Development and Reaction to COVID-19
13.4 Bristol-Myers Squibb
13.4.1 Bristol-Myers Squibb Company Details
13.4.2 Bristol-Myers Squibb Business Overview and Its Total Revenue
13.4.3 Bristol-Myers Squibb Drugs for Oncology Introduction
13.4.4 Bristol-Myers Squibb Revenue in Drugs for Oncology Business (2015-2020)
13.4.5 Bristol-Myers Squibb Recent Development and Reaction to COVID-19
13.5 Johnson & Johnson
13.5.1 Johnson & Johnson Company Details
13.5.2 Johnson & Johnson Business Overview and Its Total Revenue
13.5.3 Johnson & Johnson Drugs for Oncology Introduction
13.5.4 Johnson & Johnson Revenue in Drugs for Oncology Business (2015-2020)
13.5.5 Johnson & Johnson Recent Development and Reaction to COVID-19
13.6 Merck & Co.
13.6.1 Merck & Co. Company Details
13.6.2 Merck & Co. Business Overview and Its Total Revenue
13.6.3 Merck & Co. Drugs for Oncology Introduction
13.6.4 Merck & Co. Revenue in Drugs for Oncology Business (2015-2020)
13.6.5 Merck & Co. Recent Development and Reaction to COVID-19
13.7 AstraZeneca
13.7.1 AstraZeneca Company Details
13.7.2 AstraZeneca Business Overview and Its Total Revenue
13.7.3 AstraZeneca Drugs for Oncology Introduction
13.7.4 AstraZeneca Revenue in Drugs for Oncology Business (2015-2020)
13.7.5 AstraZeneca Recent Development and Reaction to COVID-19
13.8 Pfizer
13.8.1 Pfizer Company Details
13.8.2 Pfizer Business Overview and Its Total Revenue
13.8.3 Pfizer Drugs for Oncology Introduction
13.8.4 Pfizer Revenue in Drugs for Oncology Business (2015-2020)
13.8.5 Pfizer Recent Development and Reaction to COVID-19
13.9 Amgen
13.9.1 Amgen Company Details
13.9.2 Amgen Business Overview and Its Total Revenue
13.9.3 Amgen Drugs for Oncology Introduction
13.9.4 Amgen Revenue in Drugs for Oncology Business (2015-2020)
13.9.5 Amgen Recent Development and Reaction to COVID-19
13.10 Eli Lilly
13.10.1 Eli Lilly Company Details
13.10.2 Eli Lilly Business Overview and Its Total Revenue
13.10.3 Eli Lilly Drugs for Oncology Introduction
13.10.4 Eli Lilly Revenue in Drugs for Oncology Business (2015-2020)
13.10.5 Eli Lilly Recent Development and Reaction to COVID-19
13.11 AbbVie
10.11.1 AbbVie Company Details
10.11.2 AbbVie Business Overview and Its Total Revenue
10.11.3 AbbVie Drugs for Oncology Introduction
10.11.4 AbbVie Revenue in Drugs for Oncology Business (2015-2020)
10.11.5 AbbVie Recent Development and Reaction to COVID-19
13.12 Takeda
10.12.1 Takeda Company Details
10.12.2 Takeda Business Overview and Its Total Revenue
10.12.3 Takeda Drugs for Oncology Introduction
10.12.4 Takeda Revenue in Drugs for Oncology Business (2015-2020)
10.12.5 Takeda Recent Development and Reaction to COVID-19
13.13 Astellas
10.13.1 Astellas Company Details
10.13.2 Astellas Business Overview and Its Total Revenue
10.13.3 Astellas Drugs for Oncology Introduction
10.13.4 Astellas Revenue in Drugs for Oncology Business (2015-2020)
10.13.5 Astellas Recent Development and Reaction to COVID-19
13.14 Ipsen
10.14.1 Ipsen Company Details
10.14.2 Ipsen Business Overview and Its Total Revenue
10.14.3 Ipsen Drugs for Oncology Introduction
10.14.4 Ipsen Revenue in Drugs for Oncology Business (2015-2020)
10.14.5 Ipsen Recent Development and Reaction to COVID-19
13.15 Sanofi
10.15.1 Sanofi Company Details
10.15.2 Sanofi Business Overview and Its Total Revenue
10.15.3 Sanofi Drugs for Oncology Introduction
10.15.4 Sanofi Revenue in Drugs for Oncology Business (2015-2020)
10.15.5 Sanofi Recent Development and Reaction to COVID-19
13.16 Bayer
10.16.1 Bayer Company Details
10.16.2 Bayer Business Overview and Its Total Revenue
10.16.3 Bayer Drugs for Oncology Introduction
10.16.4 Bayer Revenue in Drugs for Oncology Business (2015-2020)
10.16.5 Bayer Recent Development and Reaction to COVID-19
13.17 Biogen Idec
10.17.1 Biogen Idec Company Details
10.17.2 Biogen Idec Business Overview and Its Total Revenue
10.17.3 Biogen Idec Drugs for Oncology Introduction
10.17.4 Biogen Idec Revenue in Drugs for Oncology Business (2015-2020)
10.17.5 Biogen Idec Recent Development and Reaction to COVID-19
13.18 Teva
10.18.1 Teva Company Details
10.18.2 Teva Business Overview and Its Total Revenue
10.18.3 Teva Drugs for Oncology Introduction
10.18.4 Teva Revenue in Drugs for Oncology Business (2015-2020)
10.18.5 Teva Recent Development and Reaction to COVID-19
13.19 Otsuka
10.19.1 Otsuka Company Details
10.19.2 Otsuka Business Overview and Its Total Revenue
10.19.3 Otsuka Drugs for Oncology Introduction
10.19.4 Otsuka Revenue in Drugs for Oncology Business (2015-2020)
10.19.5 Otsuka Recent Development and Reaction to COVID-19
13.20 Eisai
10.20.1 Eisai Company Details
10.20.2 Eisai Business Overview and Its Total Revenue
10.20.3 Eisai Drugs for Oncology Introduction
10.20.4 Eisai Revenue in Drugs for Oncology Business (2015-2020)
10.20.5 Eisai Recent Development and Reaction to COVID-19
13.21 Merck KGaA
10.21.1 Merck KGaA Company Details
10.21.2 Merck KGaA Business Overview and Its Total Revenue
10.21.3 Merck KGaA Drugs for Oncology Introduction
10.21.4 Merck KGaA Revenue in Drugs for Oncology Business (2015-2020)
10.21.5 Merck KGaA Recent Development and Reaction to COVID-19
13.22 Gilead Sciences
10.22.1 Gilead Sciences Company Details
10.22.2 Gilead Sciences Business Overview and Its Total Revenue
10.22.3 Gilead Sciences Drugs for Oncology Introduction
10.22.4 Gilead Sciences Revenue in Drugs for Oncology Business (2015-2020)
10.22.5 Gilead Sciences Recent Development and Reaction to COVID-19
14ANALYST'S VIEWPOINTS/CONCLUSIONS
15APPENDIX
15.1 Research Methodology
15.1.1 Methodology/Research Approach
15.1.2 Data Source
15.2 Disclaimer
15.3 Author Details
LIST OF TABLES
Table 1. Drugs for Oncology Key Market Segments
Table 2. Key Players Covered: Ranking by Drugs for Oncology Revenue
Table 3. Ranking of Global Top Drugs for Oncology Manufacturers by Revenue (US$ Million) in 2019
Table 4. Global Drugs for Oncology Market Size Growth Rate by Type (US$ Million): 2020 VS 2026
Table 5. Key Players of Chemotherapy
Table 6. Key Players of Targeted Therapy
Table 7. Key Players of Immunotherapy (Biologic Therapy)
Table 8. Key Players of Hormonal Therapy
Table 9. Key Players of Others
Table 10. COVID-19 Impact Global Market: (Four Drugs for Oncology Market Size Forecast Scenarios)
Table 11. Opportunities and Trends for Drugs for Oncology Players in the COVID-19 Landscape
Table 12. Present Opportunities in China & Elsewhere Due to the Coronavirus Crisis
Table 13. Key Regions/Countries Measures against Covid-19 Impact
Table 14. Proposal for Drugs for Oncology Players to Combat Covid-19 Impact
Table 15. Global Drugs for Oncology Market Size Growth by Application (US$ Million): 2020 VS 2026
Table 16. Global Drugs for Oncology Market Size by Regions (US$ Million): 2020 VS 2026
Table 17. Global Drugs for Oncology Market Size by Regions (2015-2020) (US$ Million)
Table 18. Global Drugs for Oncology Market Share by Regions (2015-2020)
Table 19. Global Drugs for Oncology Forecasted Market Size by Regions (2021-2026) (US$ Million)
Table 20. Global Drugs for Oncology Market Share by Regions (2021-2026)
Table 21. Market Top Trends
Table 22. Key Drivers: Impact Analysis
Table 23. Key Challenges
Table 24. Drugs for Oncology Market Growth Strategy
Table 25. Main Points Interviewed from Key Drugs for Oncology Players
Table 26. Global Drugs for Oncology Revenue by Players (2015-2020) (Million US$)
Table 27. Global Drugs for Oncology Market Share by Players (2015-2020)
Table 28. Global Top Drugs for Oncology Players by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Drugs for Oncology as of 2019)
Table 29. Global Drugs for Oncology by Players Market Concentration Ratio (CR5 and HHI)
Table 30. Key Players Headquarters and Area Served
Table 31. Key Players Drugs for Oncology Product Solution and Service
Table 32. Date of Enter into Drugs for Oncology Market
Table 33. Mergers & Acquisitions, Expansion Plans
Table 34. Global Drugs for Oncology Market Size by Type (2015-2020) (Million US$)
Table 35. Global Drugs for Oncology Market Size Share by Type (2015-2020)
Table 36. Global Drugs for Oncology Revenue Market Share by Type (2021-2026)
Table 37. Global Drugs for Oncology Market Size Share by Application (2015-2020)
Table 38. Global Drugs for Oncology Market Size by Application (2015-2020) (Million US$)
Table 39. Global Drugs for Oncology Market Size Share by Application (2021-2026)
Table 40. North America Key Players Drugs for Oncology Revenue (2019-2020) (Million US$)
Table 41. North America Key Players Drugs for Oncology Market Share (2019-2020)
Table 42. North America Drugs for Oncology Market Size by Type (2015-2020) (Million US$)
Table 43. North America Drugs for Oncology Market Share by Type (2015-2020)
Table 44. North America Drugs for Oncology Market Size by Application (2015-2020) (Million US$)
Table 45. North America Drugs for Oncology Market Share by Application (2015-2020)
Table 46. Europe Key Players Drugs for Oncology Revenue (2019-2020) (Million US$)
Table 47. Europe Key Players Drugs for Oncology Market Share (2019-2020)
Table 48. Europe Drugs for Oncology Market Size by Type (2015-2020) (Million US$)
Table 49. Europe Drugs for Oncology Market Share by Type (2015-2020)
Table 50. Europe Drugs for Oncology Market Size by Application (2015-2020) (Million US$)
Table 51. Europe Drugs for Oncology Market Share by Application (2015-2020)
Table 52. China Key Players Drugs for Oncology Revenue (2019-2020) (Million US$)
Table 53. China Key Players Drugs for Oncology Market Share (2019-2020)
Table 54. China Drugs for Oncology Market Size by Type (2015-2020) (Million US$)
Table 55. China Drugs for Oncology Market Share by Type (2015-2020)
Table 56. China Drugs for Oncology Market Size by Application (2015-2020) (Million US$)
Table 57. China Drugs for Oncology Market Share by Application (2015-2020)
Table 58. Japan Key Players Drugs for Oncology Revenue (2019-2020) (Million US$)
Table 59. Japan Key Players Drugs for Oncology Market Share (2019-2020)
Table 60. Japan Drugs for Oncology Market Size by Type (2015-2020) (Million US$)
Table 61. Japan Drugs for Oncology Market Share by Type (2015-2020)
Table 62. Japan Drugs for Oncology Market Size by Application (2015-2020) (Million US$)
Table 63. Japan Drugs for Oncology Market Share by Application (2015-2020)
Table 64. Southeast Asia Key Players Drugs for Oncology Revenue (2019-2020) (Million US$)
Table 65. Southeast Asia Key Players Drugs for Oncology Market Share (2019-2020)
Table 66. Southeast Asia Drugs for Oncology Market Size by Type (2015-2020) (Million US$)
Table 67. Southeast Asia Drugs for Oncology Market Share by Type (2015-2020)
Table 68. Southeast Asia Drugs for Oncology Market Size by Application (2015-2020) (Million US$)
Table 69. Southeast Asia Drugs for Oncology Market Share by Application (2015-2020)
Table 70. India Key Players Drugs for Oncology Revenue (2019-2020) (Million US$)
Table 71. India Key Players Drugs for Oncology Market Share (2019-2020)
Table 72. India Drugs for Oncology Market Size by Type (2015-2020) (Million US$)
Table 73. India Drugs for Oncology Market Share by Type (2015-2020)
Table 74. India Drugs for Oncology Market Size by Application (2015-2020) (Million US$)
Table 75. India Drugs for Oncology Market Share by Application (2015-2020)
Table 76. Central & South America Key Players Drugs for Oncology Revenue (2019-2020) (Million US$)
Table 77. Central & South America Key Players Drugs for Oncology Market Share (2019-2020)
Table 78. Central & South America Drugs for Oncology Market Size by Type (2015-2020) (Million US$)
Table 79. Central & South America Drugs for Oncology Market Share by Type (2015-2020)
Table 80. Central & South America Drugs for Oncology Market Size by Application (2015-2020) (Million US$)
Table 81. Central & South America Drugs for Oncology Market Share by Application (2015-2020)
Table 82. Roche Company Details
Table 83. Roche Business Overview
Table 84. Roche Product
Table 85. Roche Revenue in Drugs for Oncology Business (2015-2020) (Million US$)
Table 86. Roche Recent Development
Table 87. Celgene Company Details
Table 88. Celgene Business Overview
Table 89. Celgene Product
Table 90. Celgene Revenue in Drugs for Oncology Business (2015-2020) (Million US$)
Table 91. Celgene Recent Development
Table 92. Novartis Company Details
Table 93. Novartis Business Overview
Table 94. Novartis Product
Table 95. Novartis Revenue in Drugs for Oncology Business (2015-2020) (Million US$)
Table 96. Novartis Recent Development
Table 97. Bristol-Myers Squibb Company Details
Table 98. Bristol-Myers Squibb Business Overview
Table 99. Bristol-Myers Squibb Product
Table 100. Bristol-Myers Squibb Revenue in Drugs for Oncology Business (2015-2020) (Million US$)
Table 101. Bristol-Myers Squibb Recent Development
Table 102. Johnson & Johnson Company Details
Table 103. Johnson & Johnson Business Overview
Table 104. Johnson & Johnson Product
Table 105. Johnson & Johnson Revenue in Drugs for Oncology Business (2015-2020) (Million US$)
Table 106. Johnson & Johnson Recent Development
Table 107. Merck & Co. Company Details
Table 108. Merck & Co. Business Overview
Table 109. Merck & Co. Product
Table 110. Merck & Co. Revenue in Drugs for Oncology Business (2015-2020) (Million US$)
Table 111. Merck & Co. Recent Development
Table 112. AstraZeneca Company Details
Table 113. AstraZeneca Business Overview
Table 114. AstraZeneca Product
Table 115. AstraZeneca Revenue in Drugs for Oncology Business (2015-2020) (Million US$)
Table 116. AstraZeneca Recent Development
Table 117. Pfizer Business Overview
Table 118. Pfizer Product
Table 119. Pfizer Company Details
Table 120. Pfizer Revenue in Drugs for Oncology Business (2015-2020) (Million US$)
Table 121. Pfizer Recent Development
Table 122. Amgen Company Details
Table 123. Amgen Business Overview
Table 124. Amgen Product
Table 125. Amgen Revenue in Drugs for Oncology Business (2015-2020) (Million US$)
Table 126. Amgen Recent Development
Table 127. Eli Lilly Company Details
Table 128. Eli Lilly Business Overview
Table 129. Eli Lilly Product
Table 130. Eli Lilly Revenue in Drugs for Oncology Business (2015-2020) (Million US$)
Table 131. Eli Lilly Recent Development
Table 132. AbbVie Company Details
Table 133. AbbVie Business Overview
Table 134. AbbVie Product
Table 135. AbbVie Revenue in Drugs for Oncology Business (2015-2020) (Million US$)
Table 136. AbbVie Recent Development
Table 137. Takeda Company Details
Table 138. Takeda Business Overview
Table 139. Takeda Product
Table 140. Takeda Revenue in Drugs for Oncology Business (2015-2020) (Million US$)
Table 141. Takeda Recent Development
Table 142. Astellas Company Details
Table 143. Astellas Business Overview
Table 144. Astellas Product
Table 145. Astellas Revenue in Drugs for Oncology Business (2015-2020) (Million US$)
Table 146. Astellas Recent Development
Table 147. Ipsen Company Details
Table 148. Ipsen Business Overview
Table 149. Ipsen Product
Table 150. Ipsen Revenue in Drugs for Oncology Business (2015-2020) (Million US$)
Table 151. Ipsen Recent Development
Table 152. Sanofi Company Details
Table 153. Sanofi Business Overview
Table 154. Sanofi Product
Table 155. Sanofi Revenue in Drugs for Oncology Business (2015-2020) (Million US$)
Table 156. Sanofi Recent Development
Table 157. Bayer Company Details
Table 158. Bayer Business Overview
Table 159. Bayer Product
Table 160. Bayer Revenue in Drugs for Oncology Business (2015-2020) (Million US$)
Table 161. Bayer Recent Development
Table 162. Biogen Idec Company Details
Table 163. Biogen Idec Business Overview
Table 164. Biogen Idec Product
Table 165. Biogen Idec Revenue in Drugs for Oncology Business (2015-2020) (Million US$)
Table 166. Biogen Idec Recent Development
Table 167. Teva Company Details
Table 168. Teva Business Overview
Table 169. Teva Product
Table 170. Teva Revenue in Drugs for Oncology Business (2015-2020) (Million US$)
Table 171. Teva Recent Development
Table 172. Otsuka Company Details
Table 173. Otsuka Business Overview
Table 174. Otsuka Product
Table 175. Otsuka Revenue in Drugs for Oncology Business (2015-2020) (Million US$)
Table 176. Otsuka Recent Development
Table 177. Eisai Company Details
Table 178. Eisai Business Overview
Table 179. Eisai Product
Table 180. Eisai Revenue in Drugs for Oncology Business (2015-2020) (Million US$)
Table 181. Eisai Recent Development
Table 182. Merck KGaA Company Details
Table 183. Merck KGaA Business Overview
Table 184. Merck KGaA Product
Table 185. Merck KGaA Revenue in Drugs for Oncology Business (2015-2020) (Million US$)
Table 186. Merck KGaA Recent Development
Table 187. Gilead Sciences Company Details
Table 188. Gilead Sciences Business Overview
Table 189. Gilead Sciences Product
Table 190. Gilead Sciences Revenue in Drugs for Oncology Business (2015-2020) (Million US$)
Table 191. Gilead Sciences Recent Development
Table 192. Research Programs/Design for This Report
Table 193. Key Data Information from Secondary Sources
Table 194. Key Data Information from Primary Sources
Table 1. Drugs for Oncology Key Market Segments
Table 2. Key Players Covered: Ranking by Drugs for Oncology Revenue
Table 3. Ranking of Global Top Drugs for Oncology Manufacturers by Revenue (US$ Million) in 2019
Table 4. Global Drugs for Oncology Market Size Growth Rate by Type (US$ Million): 2020 VS 2026
Table 5. Key Players of Chemotherapy
Table 6. Key Players of Targeted Therapy
Table 7. Key Players of Immunotherapy (Biologic Therapy)
Table 8. Key Players of Hormonal Therapy
Table 9. Key Players of Others
Table 10. COVID-19 Impact Global Market: (Four Drugs for Oncology Market Size Forecast Scenarios)
Table 11. Opportunities and Trends for Drugs for Oncology Players in the COVID-19 Landscape
Table 12. Present Opportunities in China & Elsewhere Due to the Coronavirus Crisis
Table 13. Key Regions/Countries Measures against Covid-19 Impact
Table 14. Proposal for Drugs for Oncology Players to Combat Covid-19 Impact
Table 15. Global Drugs for Oncology Market Size Growth by Application (US$ Million): 2020 VS 2026
Table 16. Global Drugs for Oncology Market Size by Regions (US$ Million): 2020 VS 2026
Table 17. Global Drugs for Oncology Market Size by Regions (2015-2020) (US$ Million)
Table 18. Global Drugs for Oncology Market Share by Regions (2015-2020)
Table 19. Global Drugs for Oncology Forecasted Market Size by Regions (2021-2026) (US$ Million)
Table 20. Global Drugs for Oncology Market Share by Regions (2021-2026)
Table 21. Market Top Trends
Table 22. Key Drivers: Impact Analysis
Table 23. Key Challenges
Table 24. Drugs for Oncology Market Growth Strategy
Table 25. Main Points Interviewed from Key Drugs for Oncology Players
Table 26. Global Drugs for Oncology Revenue by Players (2015-2020) (Million US$)
Table 27. Global Drugs for Oncology Market Share by Players (2015-2020)
Table 28. Global Top Drugs for Oncology Players by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Drugs for Oncology as of 2019)
Table 29. Global Drugs for Oncology by Players Market Concentration Ratio (CR5 and HHI)
Table 30. Key Players Headquarters and Area Served
Table 31. Key Players Drugs for Oncology Product Solution and Service
Table 32. Date of Enter into Drugs for Oncology Market
Table 33. Mergers & Acquisitions, Expansion Plans
Table 34. Global Drugs for Oncology Market Size by Type (2015-2020) (Million US$)
Table 35. Global Drugs for Oncology Market Size Share by Type (2015-2020)
Table 36. Global Drugs for Oncology Revenue Market Share by Type (2021-2026)
Table 37. Global Drugs for Oncology Market Size Share by Application (2015-2020)
Table 38. Global Drugs for Oncology Market Size by Application (2015-2020) (Million US$)
Table 39. Global Drugs for Oncology Market Size Share by Application (2021-2026)
Table 40. North America Key Players Drugs for Oncology Revenue (2019-2020) (Million US$)
Table 41. North America Key Players Drugs for Oncology Market Share (2019-2020)
Table 42. North America Drugs for Oncology Market Size by Type (2015-2020) (Million US$)
Table 43. North America Drugs for Oncology Market Share by Type (2015-2020)
Table 44. North America Drugs for Oncology Market Size by Application (2015-2020) (Million US$)
Table 45. North America Drugs for Oncology Market Share by Application (2015-2020)
Table 46. Europe Key Players Drugs for Oncology Revenue (2019-2020) (Million US$)
Table 47. Europe Key Players Drugs for Oncology Market Share (2019-2020)
Table 48. Europe Drugs for Oncology Market Size by Type (2015-2020) (Million US$)
Table 49. Europe Drugs for Oncology Market Share by Type (2015-2020)
Table 50. Europe Drugs for Oncology Market Size by Application (2015-2020) (Million US$)
Table 51. Europe Drugs for Oncology Market Share by Application (2015-2020)
Table 52. China Key Players Drugs for Oncology Revenue (2019-2020) (Million US$)
Table 53. China Key Players Drugs for Oncology Market Share (2019-2020)
Table 54. China Drugs for Oncology Market Size by Type (2015-2020) (Million US$)
Table 55. China Drugs for Oncology Market Share by Type (2015-2020)
Table 56. China Drugs for Oncology Market Size by Application (2015-2020) (Million US$)
Table 57. China Drugs for Oncology Market Share by Application (2015-2020)
Table 58. Japan Key Players Drugs for Oncology Revenue (2019-2020) (Million US$)
Table 59. Japan Key Players Drugs for Oncology Market Share (2019-2020)
Table 60. Japan Drugs for Oncology Market Size by Type (2015-2020) (Million US$)
Table 61. Japan Drugs for Oncology Market Share by Type (2015-2020)
Table 62. Japan Drugs for Oncology Market Size by Application (2015-2020) (Million US$)
Table 63. Japan Drugs for Oncology Market Share by Application (2015-2020)
Table 64. Southeast Asia Key Players Drugs for Oncology Revenue (2019-2020) (Million US$)
Table 65. Southeast Asia Key Players Drugs for Oncology Market Share (2019-2020)
Table 66. Southeast Asia Drugs for Oncology Market Size by Type (2015-2020) (Million US$)
Table 67. Southeast Asia Drugs for Oncology Market Share by Type (2015-2020)
Table 68. Southeast Asia Drugs for Oncology Market Size by Application (2015-2020) (Million US$)
Table 69. Southeast Asia Drugs for Oncology Market Share by Application (2015-2020)
Table 70. India Key Players Drugs for Oncology Revenue (2019-2020) (Million US$)
Table 71. India Key Players Drugs for Oncology Market Share (2019-2020)
Table 72. India Drugs for Oncology Market Size by Type (2015-2020) (Million US$)
Table 73. India Drugs for Oncology Market Share by Type (2015-2020)
Table 74. India Drugs for Oncology Market Size by Application (2015-2020) (Million US$)
Table 75. India Drugs for Oncology Market Share by Application (2015-2020)
Table 76. Central & South America Key Players Drugs for Oncology Revenue (2019-2020) (Million US$)
Table 77. Central & South America Key Players Drugs for Oncology Market Share (2019-2020)
Table 78. Central & South America Drugs for Oncology Market Size by Type (2015-2020) (Million US$)
Table 79. Central & South America Drugs for Oncology Market Share by Type (2015-2020)
Table 80. Central & South America Drugs for Oncology Market Size by Application (2015-2020) (Million US$)
Table 81. Central & South America Drugs for Oncology Market Share by Application (2015-2020)
Table 82. Roche Company Details
Table 83. Roche Business Overview
Table 84. Roche Product
Table 85. Roche Revenue in Drugs for Oncology Business (2015-2020) (Million US$)
Table 86. Roche Recent Development
Table 87. Celgene Company Details
Table 88. Celgene Business Overview
Table 89. Celgene Product
Table 90. Celgene Revenue in Drugs for Oncology Business (2015-2020) (Million US$)
Table 91. Celgene Recent Development
Table 92. Novartis Company Details
Table 93. Novartis Business Overview
Table 94. Novartis Product
Table 95. Novartis Revenue in Drugs for Oncology Business (2015-2020) (Million US$)
Table 96. Novartis Recent Development
Table 97. Bristol-Myers Squibb Company Details
Table 98. Bristol-Myers Squibb Business Overview
Table 99. Bristol-Myers Squibb Product
Table 100. Bristol-Myers Squibb Revenue in Drugs for Oncology Business (2015-2020) (Million US$)
Table 101. Bristol-Myers Squibb Recent Development
Table 102. Johnson & Johnson Company Details
Table 103. Johnson & Johnson Business Overview
Table 104. Johnson & Johnson Product
Table 105. Johnson & Johnson Revenue in Drugs for Oncology Business (2015-2020) (Million US$)
Table 106. Johnson & Johnson Recent Development
Table 107. Merck & Co. Company Details
Table 108. Merck & Co. Business Overview
Table 109. Merck & Co. Product
Table 110. Merck & Co. Revenue in Drugs for Oncology Business (2015-2020) (Million US$)
Table 111. Merck & Co. Recent Development
Table 112. AstraZeneca Company Details
Table 113. AstraZeneca Business Overview
Table 114. AstraZeneca Product
Table 115. AstraZeneca Revenue in Drugs for Oncology Business (2015-2020) (Million US$)
Table 116. AstraZeneca Recent Development
Table 117. Pfizer Business Overview
Table 118. Pfizer Product
Table 119. Pfizer Company Details
Table 120. Pfizer Revenue in Drugs for Oncology Business (2015-2020) (Million US$)
Table 121. Pfizer Recent Development
Table 122. Amgen Company Details
Table 123. Amgen Business Overview
Table 124. Amgen Product
Table 125. Amgen Revenue in Drugs for Oncology Business (2015-2020) (Million US$)
Table 126. Amgen Recent Development
Table 127. Eli Lilly Company Details
Table 128. Eli Lilly Business Overview
Table 129. Eli Lilly Product
Table 130. Eli Lilly Revenue in Drugs for Oncology Business (2015-2020) (Million US$)
Table 131. Eli Lilly Recent Development
Table 132. AbbVie Company Details
Table 133. AbbVie Business Overview
Table 134. AbbVie Product
Table 135. AbbVie Revenue in Drugs for Oncology Business (2015-2020) (Million US$)
Table 136. AbbVie Recent Development
Table 137. Takeda Company Details
Table 138. Takeda Business Overview
Table 139. Takeda Product
Table 140. Takeda Revenue in Drugs for Oncology Business (2015-2020) (Million US$)
Table 141. Takeda Recent Development
Table 142. Astellas Company Details
Table 143. Astellas Business Overview
Table 144. Astellas Product
Table 145. Astellas Revenue in Drugs for Oncology Business (2015-2020) (Million US$)
Table 146. Astellas Recent Development
Table 147. Ipsen Company Details
Table 148. Ipsen Business Overview
Table 149. Ipsen Product
Table 150. Ipsen Revenue in Drugs for Oncology Business (2015-2020) (Million US$)
Table 151. Ipsen Recent Development
Table 152. Sanofi Company Details
Table 153. Sanofi Business Overview
Table 154. Sanofi Product
Table 155. Sanofi Revenue in Drugs for Oncology Business (2015-2020) (Million US$)
Table 156. Sanofi Recent Development
Table 157. Bayer Company Details
Table 158. Bayer Business Overview
Table 159. Bayer Product
Table 160. Bayer Revenue in Drugs for Oncology Business (2015-2020) (Million US$)
Table 161. Bayer Recent Development
Table 162. Biogen Idec Company Details
Table 163. Biogen Idec Business Overview
Table 164. Biogen Idec Product
Table 165. Biogen Idec Revenue in Drugs for Oncology Business (2015-2020) (Million US$)
Table 166. Biogen Idec Recent Development
Table 167. Teva Company Details
Table 168. Teva Business Overview
Table 169. Teva Product
Table 170. Teva Revenue in Drugs for Oncology Business (2015-2020) (Million US$)
Table 171. Teva Recent Development
Table 172. Otsuka Company Details
Table 173. Otsuka Business Overview
Table 174. Otsuka Product
Table 175. Otsuka Revenue in Drugs for Oncology Business (2015-2020) (Million US$)
Table 176. Otsuka Recent Development
Table 177. Eisai Company Details
Table 178. Eisai Business Overview
Table 179. Eisai Product
Table 180. Eisai Revenue in Drugs for Oncology Business (2015-2020) (Million US$)
Table 181. Eisai Recent Development
Table 182. Merck KGaA Company Details
Table 183. Merck KGaA Business Overview
Table 184. Merck KGaA Product
Table 185. Merck KGaA Revenue in Drugs for Oncology Business (2015-2020) (Million US$)
Table 186. Merck KGaA Recent Development
Table 187. Gilead Sciences Company Details
Table 188. Gilead Sciences Business Overview
Table 189. Gilead Sciences Product
Table 190. Gilead Sciences Revenue in Drugs for Oncology Business (2015-2020) (Million US$)
Table 191. Gilead Sciences Recent Development
Table 192. Research Programs/Design for This Report
Table 193. Key Data Information from Secondary Sources
Table 194. Key Data Information from Primary Sources
LIST OF FIGURES
Figure 1. Global Drugs for Oncology Market Share by Type: 2020 VS 2026
Figure 2. Chemotherapy Features
Figure 3. Targeted Therapy Features
Figure 4. Immunotherapy (Biologic Therapy) Features
Figure 5. Hormonal Therapy Features
Figure 6. Others Features
Figure 7. Global Drugs for Oncology Market Share by Application: 2020 VS 2026
Figure 8. Blood Cancer Case Studies
Figure 9. Breast Cancer Case Studies
Figure 10. Gastrointestinal Cancer Case Studies
Figure 11. Prostate Cancer Case Studies
Figure 12. Respiratory/Lung Cancer Case Studies
Figure 13. Others Case Studies
Figure 14. Drugs for Oncology Report Years Considered
Figure 15. Global Drugs for Oncology Market Size YoY Growth 2015-2026 (US$ Million)
Figure 16. Global Drugs for Oncology Market Share by Regions: 2020 VS 2026
Figure 17. Global Drugs for Oncology Market Share by Regions (2021-2026)
Figure 18. Porter's Five Forces Analysis
Figure 19. Global Drugs for Oncology Market Share by Players in 2019
Figure 20. Global Top Drugs for Oncology Players by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Drugs for Oncology as of 2019
Figure 21. The Top 10 and 5 Players Market Share by Drugs for Oncology Revenue in 2019
Figure 22. North America Drugs for Oncology Market Size YoY Growth (2015-2020) (Million US$)
Figure 23. Europe Drugs for Oncology Market Size YoY Growth (2015-2020) (Million US$)
Figure 24. China Drugs for Oncology Market Size YoY Growth (2015-2020) (Million US$)
Figure 25. Japan Drugs for Oncology Market Size YoY Growth (2015-2020) (Million US$)
Figure 26. Southeast Asia Drugs for Oncology Market Size YoY Growth (2015-2020) (Million US$)
Figure 27. India Drugs for Oncology Market Size YoY Growth (2015-2020) (Million US$)
Figure 28. Central & South America Drugs for Oncology Market Size YoY Growth (2015-2020) (Million US$)
Figure 29. Roche Total Revenue (US$ Million): 2019 Compared with 2018
Figure 30. Roche Revenue Growth Rate in Drugs for Oncology Business (2015-2020)
Figure 31. Celgene Total Revenue (US$ Million): 2019 Compared with 2018
Figure 32. Celgene Revenue Growth Rate in Drugs for Oncology Business (2015-2020)
Figure 33. Novartis Total Revenue (US$ Million): 2019 Compared with 2018
Figure 34. Novartis Revenue Growth Rate in Drugs for Oncology Business (2015-2020)
Figure 35. Bristol-Myers Squibb Total Revenue (US$ Million): 2019 Compared with 2018
Figure 36. Bristol-Myers Squibb Revenue Growth Rate in Drugs for Oncology Business (2015-2020)
Figure 37. Johnson & Johnson Total Revenue (US$ Million): 2019 Compared with 2018
Figure 38. Johnson & Johnson Revenue Growth Rate in Drugs for Oncology Business (2015-2020)
Figure 39. Merck & Co. Total Revenue (US$ Million): 2019 Compared with 2018
Figure 40. Merck & Co. Revenue Growth Rate in Drugs for Oncology Business (2015-2020)
Figure 41. AstraZeneca Total Revenue (US$ Million): 2019 Compared with 2018
Figure 42. AstraZeneca Revenue Growth Rate in Drugs for Oncology Business (2015-2020)
Figure 43. Pfizer Total Revenue (US$ Million): 2019 Compared with 2018
Figure 44. Pfizer Revenue Growth Rate in Drugs for Oncology Business (2015-2020)
Figure 45. Amgen Total Revenue (US$ Million): 2019 Compared with 2018
Figure 46. Amgen Revenue Growth Rate in Drugs for Oncology Business (2015-2020)
Figure 47. Eli Lilly Total Revenue (US$ Million): 2019 Compared with 2018
Figure 48. Eli Lilly Revenue Growth Rate in Drugs for Oncology Business (2015-2020)
Figure 49. AbbVie Total Revenue (US$ Million): 2019 Compared with 2018
Figure 50. AbbVie Revenue Growth Rate in Drugs for Oncology Business (2015-2020)
Figure 51. Takeda Total Revenue (US$ Million): 2019 Compared with 2018
Figure 52. Takeda Revenue Growth Rate in Drugs for Oncology Business (2015-2020)
Figure 53. Astellas Total Revenue (US$ Million): 2019 Compared with 2018
Figure 54. Astellas Revenue Growth Rate in Drugs for Oncology Business (2015-2020)
Figure 55. Ipsen Total Revenue (US$ Million): 2019 Compared with 2018
Figure 56. Ipsen Revenue Growth Rate in Drugs for Oncology Business (2015-2020)
Figure 57. Sanofi Total Revenue (US$ Million): 2019 Compared with 2018
Figure 58. Sanofi Revenue Growth Rate in Drugs for Oncology Business (2015-2020)
Figure 59. Bayer Total Revenue (US$ Million): 2019 Compared with 2018
Figure 60. Bayer Revenue Growth Rate in Drugs for Oncology Business (2015-2020)
Figure 61. Biogen Idec Total Revenue (US$ Million): 2019 Compared with 2018
Figure 62. Biogen Idec Revenue Growth Rate in Drugs for Oncology Business (2015-2020)
Figure 63. Teva Total Revenue (US$ Million): 2019 Compared with 2018
Figure 64. Teva Revenue Growth Rate in Drugs for Oncology Business (2015-2020)
Figure 65. Otsuka Total Revenue (US$ Million): 2019 Compared with 2018
Figure 66. Otsuka Revenue Growth Rate in Drugs for Oncology Business (2015-2020)
Figure 67. Eisai Total Revenue (US$ Million): 2019 Compared with 2018
Figure 68. Eisai Revenue Growth Rate in Drugs for Oncology Business (2015-2020)
Figure 69. Bottom-up and Top-down Approaches for This Report
Figure 70. Data Triangulation
Figure 71. Key Executives Interviewed
Figure 1. Global Drugs for Oncology Market Share by Type: 2020 VS 2026
Figure 2. Chemotherapy Features
Figure 3. Targeted Therapy Features
Figure 4. Immunotherapy (Biologic Therapy) Features
Figure 5. Hormonal Therapy Features
Figure 6. Others Features
Figure 7. Global Drugs for Oncology Market Share by Application: 2020 VS 2026
Figure 8. Blood Cancer Case Studies
Figure 9. Breast Cancer Case Studies
Figure 10. Gastrointestinal Cancer Case Studies
Figure 11. Prostate Cancer Case Studies
Figure 12. Respiratory/Lung Cancer Case Studies
Figure 13. Others Case Studies
Figure 14. Drugs for Oncology Report Years Considered
Figure 15. Global Drugs for Oncology Market Size YoY Growth 2015-2026 (US$ Million)
Figure 16. Global Drugs for Oncology Market Share by Regions: 2020 VS 2026
Figure 17. Global Drugs for Oncology Market Share by Regions (2021-2026)
Figure 18. Porter's Five Forces Analysis
Figure 19. Global Drugs for Oncology Market Share by Players in 2019
Figure 20. Global Top Drugs for Oncology Players by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Drugs for Oncology as of 2019
Figure 21. The Top 10 and 5 Players Market Share by Drugs for Oncology Revenue in 2019
Figure 22. North America Drugs for Oncology Market Size YoY Growth (2015-2020) (Million US$)
Figure 23. Europe Drugs for Oncology Market Size YoY Growth (2015-2020) (Million US$)
Figure 24. China Drugs for Oncology Market Size YoY Growth (2015-2020) (Million US$)
Figure 25. Japan Drugs for Oncology Market Size YoY Growth (2015-2020) (Million US$)
Figure 26. Southeast Asia Drugs for Oncology Market Size YoY Growth (2015-2020) (Million US$)
Figure 27. India Drugs for Oncology Market Size YoY Growth (2015-2020) (Million US$)
Figure 28. Central & South America Drugs for Oncology Market Size YoY Growth (2015-2020) (Million US$)
Figure 29. Roche Total Revenue (US$ Million): 2019 Compared with 2018
Figure 30. Roche Revenue Growth Rate in Drugs for Oncology Business (2015-2020)
Figure 31. Celgene Total Revenue (US$ Million): 2019 Compared with 2018
Figure 32. Celgene Revenue Growth Rate in Drugs for Oncology Business (2015-2020)
Figure 33. Novartis Total Revenue (US$ Million): 2019 Compared with 2018
Figure 34. Novartis Revenue Growth Rate in Drugs for Oncology Business (2015-2020)
Figure 35. Bristol-Myers Squibb Total Revenue (US$ Million): 2019 Compared with 2018
Figure 36. Bristol-Myers Squibb Revenue Growth Rate in Drugs for Oncology Business (2015-2020)
Figure 37. Johnson & Johnson Total Revenue (US$ Million): 2019 Compared with 2018
Figure 38. Johnson & Johnson Revenue Growth Rate in Drugs for Oncology Business (2015-2020)
Figure 39. Merck & Co. Total Revenue (US$ Million): 2019 Compared with 2018
Figure 40. Merck & Co. Revenue Growth Rate in Drugs for Oncology Business (2015-2020)
Figure 41. AstraZeneca Total Revenue (US$ Million): 2019 Compared with 2018
Figure 42. AstraZeneca Revenue Growth Rate in Drugs for Oncology Business (2015-2020)
Figure 43. Pfizer Total Revenue (US$ Million): 2019 Compared with 2018
Figure 44. Pfizer Revenue Growth Rate in Drugs for Oncology Business (2015-2020)
Figure 45. Amgen Total Revenue (US$ Million): 2019 Compared with 2018
Figure 46. Amgen Revenue Growth Rate in Drugs for Oncology Business (2015-2020)
Figure 47. Eli Lilly Total Revenue (US$ Million): 2019 Compared with 2018
Figure 48. Eli Lilly Revenue Growth Rate in Drugs for Oncology Business (2015-2020)
Figure 49. AbbVie Total Revenue (US$ Million): 2019 Compared with 2018
Figure 50. AbbVie Revenue Growth Rate in Drugs for Oncology Business (2015-2020)
Figure 51. Takeda Total Revenue (US$ Million): 2019 Compared with 2018
Figure 52. Takeda Revenue Growth Rate in Drugs for Oncology Business (2015-2020)
Figure 53. Astellas Total Revenue (US$ Million): 2019 Compared with 2018
Figure 54. Astellas Revenue Growth Rate in Drugs for Oncology Business (2015-2020)
Figure 55. Ipsen Total Revenue (US$ Million): 2019 Compared with 2018
Figure 56. Ipsen Revenue Growth Rate in Drugs for Oncology Business (2015-2020)
Figure 57. Sanofi Total Revenue (US$ Million): 2019 Compared with 2018
Figure 58. Sanofi Revenue Growth Rate in Drugs for Oncology Business (2015-2020)
Figure 59. Bayer Total Revenue (US$ Million): 2019 Compared with 2018
Figure 60. Bayer Revenue Growth Rate in Drugs for Oncology Business (2015-2020)
Figure 61. Biogen Idec Total Revenue (US$ Million): 2019 Compared with 2018
Figure 62. Biogen Idec Revenue Growth Rate in Drugs for Oncology Business (2015-2020)
Figure 63. Teva Total Revenue (US$ Million): 2019 Compared with 2018
Figure 64. Teva Revenue Growth Rate in Drugs for Oncology Business (2015-2020)
Figure 65. Otsuka Total Revenue (US$ Million): 2019 Compared with 2018
Figure 66. Otsuka Revenue Growth Rate in Drugs for Oncology Business (2015-2020)
Figure 67. Eisai Total Revenue (US$ Million): 2019 Compared with 2018
Figure 68. Eisai Revenue Growth Rate in Drugs for Oncology Business (2015-2020)
Figure 69. Bottom-up and Top-down Approaches for This Report
Figure 70. Data Triangulation
Figure 71. Key Executives Interviewed
